alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

###### Drug Enforcement Administration

          - [Docket No. DEA-392]

# ACTION:

Notice of application.

# DATES:

Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 19, 2018.

# ADDRESSES:

Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

# SUPPLEMENTARY INFORMATION:

The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on July 4, 2017, Alcami Wisconsin Corporation, W130 N10497 Washington Drive, Germantown, Wisconsin 53022 applied to be registered as a bulk manufacturer of thebaine (9333), a basic class of controlled substance listed in schedule II.

The company states they plan to conduct clinical trials.

Dated: January 5, 2018.

Susan A. Gibson,

Deputy Assistant Administrator.

[FR Doc. 2018-00709 Filed 1-17-18; 8:45 am]

 BILLING CODE 4410-09-P
EXHIBIT
32.2





MAXUS
REALTY TRUST, INC.





CERTIFICATION
OF CHIEF EXECUTIVE OFFICER PURSUANT TO


18 U.S.C.
SECTION 1350,


AS
ADOPTED PURSUANT TO


SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002





In
connection with the Quarterly Report of Maxus Realty Trust, Inc. (the “Trust”)
on Form 10-QSB for the period ending March 31, 2008 as filed with the Securities
and Exchange Commission on the date hereof (the “Report”), I, John W. Alvey,
Vice President and Chief Financial and Accounting Officer of the Trust, certify,
pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the
Sarbanes-Oxley Act of 2002, that to my knowledge:





(1) The
Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





(2) The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Trust as of March 31,
2008 (the last date of the period covered by the Report).








/s/
John W. Alvey


John W.
Alvey


Treasurer
and


Principal
Financial Officer





May 13,
2008
EX PARTE Timothy Glenn BURCH, Jr.

1151201 (2150403)

Supreme Court of Alabama.

October 21, 2016

**DECISION WITHOUT PUBLISHED OPINION**

Cert. denied.
p.1 

OAR Box 1672 

Prepped by Charmelle Mathews 

Document Number: 

^8)II-C-19 

Docket Number: 

A-98-13 

Printed 9/30/2008 11:01:00 AM Sheet 48 of 132 
P.2 

A 98 13 

From: 

To: 

Subject: 

Copies to: 

Date sent: 

Bill Allmond 

NACD 

Self <PES1 RTP/GLAFLAM> 

BILLNACD <BILLNACD@aol.com> 

EPA Survey and Site Visits 

STEVE SHEDD <SHEDD.STEVE@epamail.epa.gov> 

Fri, 20 Mar 1998 15:40:41 -0500 (EST) 

Bill: 

Rather than call you on a Friday afternoon, I thought I'd send a brief 

message and let you call me back today if you wish. Otherwise, I'll 

try to call you on Monday. 

We are ready to expand our survey mailing list by extracting 

companies from your membership directory that have several chemical 

codes of interest to us. Would you like us to send you a list of our 

picks, rather than your suggesting some to us as being appropriate? 

We also need to firm up our site visits in Texas, and would like to 

add one more in the general Houston area (if possible). Can we 

discuss possible NACD member candidates (other than Ashland, which is 

the company we have already talked to)? 

I hope you can participate in the EPA's P-MACT meeting on Tuesday, at 

least by calling in. 

Thanks, 

Greg LaFlam 

PES, Inc. 

0^ 

Greg LaFlam _. 1 „ Mon, 13 Apr 1998 14:52:15
<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          JAN-03-1998
<PERIOD-END>                               JUN-28-1997
<CASH>                                           2,302
<SECURITIES>                                         0
<RECEIVABLES>                                    9,794
<ALLOWANCES>                                     1,189
<INVENTORY>                                     50,697
<CURRENT-ASSETS>                                70,737
<PP&E>                                          38,440
<DEPRECIATION>                                  24,311
<TOTAL-ASSETS>                                  92,232
<CURRENT-LIABILITIES>                           19,094
<BONDS>                                         15,265
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         9,539
<OTHER-SE>                                      44,825
<TOTAL-LIABILITY-AND-EQUITY>                    92,232
<SALES>                                         29,474
<TOTAL-REVENUES>                                29,474
<CGS>                                           14,227
<TOTAL-COSTS>                                   14,227
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 624
<INCOME-PRETAX>                                (4,798)
<INCOME-TAX>                                   (1,919)
<INCOME-CONTINUING>                            (2,879)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (2,879)
<EPS-PRIMARY>                                   (0.30)
<EPS-DILUTED>                                   (0.30)
        

</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THE FINANCIAL DATA SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION
EXTRACTED FROM THE COMPANY'S QUARTERLY REPORT CONSOLIDATED FINANCIAL
STATEMENTS FOR THE 9 MONTHS ENDED SEPTEMBER 30, 1998 AND IS QUALIFIED
IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-END>                               SEP-30-1998
<CASH>                                             482
<SECURITIES>                                         0
<RECEIVABLES>                                    1,706
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 3,551
<PP&E>                                          30,494
<DEPRECIATION>                                  (4,007)
<TOTAL-ASSETS>                                  30,628
<CURRENT-LIABILITIES>                            3,378
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        11,175
<OTHER-SE>                                          25
<TOTAL-LIABILITY-AND-EQUITY>                    30,628
<SALES>                                          6,164
<TOTAL-REVENUES>                                 6,974
<CGS>                                            3,839
<TOTAL-COSTS>                                    1,113
<OTHER-EXPENSES>                                 2,697
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 521
<INCOME-PRETAX>                                 (1,196)
<INCOME-TAX>                                      (215) 
<INCOME-CONTINUING>                               (981)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                      (981)
<EPS-PRIMARY>                                     (.03)
<EPS-DILUTED>                                     (.02)
        

</TABLE>
NORTHPORT HEALTH SERVICES OF FLORIDA, LLC and NHS Management, LLC, Appellants, v. ESTATE OF Gertrude R. CHAMPAGNE BY AND THROUGH Gloria OLSEN, Personal Representative, Appellee.

Case No. 5D17-2693

District Court of Appeal of Florida, Fifth District.

Opinion filed April 13, 2018

Dale R. Sisco and Kristi Neher Davisson, of Sisco-Law, Tampa, for Appellants.

Megan L Gisclar and Joanna Greber Dettloff, of Wilkes & McHugh, P.A., Tampa, for Appellee.

WALLIS, J.

Northport Health Services of Florida, LLC d/b/a West Melbourne Health and Rehabilitation Center, appeals the trial court's order denying Northport's motion to compel arbitration with Gloria Olsen, as personal representative of the Estate of Gertrude R. Champagne.

We have recently addressed the enforceability of an identical arbitration agreement in *Northport Health Services of Florida, LLC v. Louis*, 240 So.3d 120 (Fla. 5th DCA Mar. 2, 2018). We held in *Louis* that the provision requiring Alabama's Rules of Evidence to control the admissibility of evidence at arbitration was against public policy, and that the provision was severable because it concerns procedure. *Id.* at ---- at D506. However, we also held that the provision requiring the application of Alabama Rules of Civil Procedure to the parties' conduct of pre-hearing discovery does not violate public policy because no convincing argument was raised as to why the application is problematic. *Id.*

Here, the parties raise essentially the same arguments. Accordingly, we reverse and remand with instructions to the trial court to grant Northport's motion to compel and to sever from the arbitration agreement the provision applying the Alabama Rules of Evidence to the admissibility of evidence at the arbitration hearing. *Id.*; *see also**Hancock v. Northport Health Servs. of Fla., LLC*, 150 So.3d 1262, 1263 (Fla. 5th DCA 2014) (affirming an order compelling arbitration of an identical arbitration agreement).

REVERSED and REMANDED, with Instructions.

SAWAYA and EDWARDS, JJ., concur.
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

v. No. 99-4629

MATTHEW JOHNSON,

Defendant-Appellant.

Appeal from the United States District Court

for the Eastern District of Virginia, at Newport News.

Robert G. Doumar, Senior District Judge.

(CR-98-76)

Submitted: January 27, 2000

Decided: February 11, 2000

Before WILLIAMS, MICHAEL, and MOTZ, Circuit Judges.

_________________________________________________________________

Affirmed in part and dismissed in part by unpublished per curiam

opinion.

_________________________________________________________________

COUNSEL

James S. Ellenson, Newport News, Virginia, for Appellant. Helen F.

Fahey, United States Attorney, Robert E. Bradenham, II, Assistant

United States Attorney, Billy B. Ruhling, II, Third Year Law Student,

Norfolk, Virginia, for Appellee.

_________________________________________________________________
Unpublished opinions are not binding precedent in this circuit. See

Local Rule 36(c).

_________________________________________________________________

OPINION

PER CURIAM:

Matthew Johnson was convicted of distribution of cocaine base in

violation of 21 U.S.C. § 841(a)(1) (1994) and subsequently sentenced

to 168 months imprisonment. On appeal, he maintains that the district

court erred by: (1) allowing the testimony of a confidential informant

pertaining to prior drug transactions between himself and Johnson; (2)

applying a two-point enhancement for presence of a dangerous

weapon under U.S. Sentencing Guidelines Manual § 2D1.1(b)(1)

(1998); and (3) refusing to grant a downward departure at sentencing

on the ground that Johnson's criminal history was overrepresented.

We find that the district court did not abuse its discretion in allowing the testimony of the confidential informant concerning his prior

drug transactions with Johnson under Fed. R. Evid. 404(b), see United

States v. Mark, 943 F.2d 444, 447 (4th Cir. 1991), and that any error

was harmless in light of the overwhelming evidence of guilt, see

United States v. Brooks, 111 F.3d 365, 371 (4th Cir. 1997). Additionally, we find that the district court's two-point enhancement in Johnson's sentence for possession of a dangerous weapon was appropriate

under the circumstances of this case. See USSG § 2D1.1, comment.

(n.3). Last, the district court's decision not to depart from the guidelines is not subject to review when, as here, the district court's refusal

is not based on the mistaken belief that the court lacked the authority

to depart. See United States v. Bayerle, 898 F.2d 28, 31 (4th Cir.

1990).

Accordingly, we affirm Johnson's conviction and sentence and dismiss that portion of the appeal that challenges the district court's decision not to depart from the guidelines. We dispense with oral

argument because the facts and legal contentions are adequately presented in the materials before the court, and oral argument would not

aid the decisional process.

AFFIRMED IN PART; DISMISSED IN PART

 2
Paul WEDMORE, Appellant, v. Kevin Paul O'CONNOR and Fran O'Connor, Appellees.

Case No. 2D17-2295

District Court of Appeal of Florida, Second District.

Opinion filed March 2, 2018

Jeffrey D. Jensen and T.R. Unice, Jr. of Unice Salzman Jensen, P.A., Trinity, for Appellant.

Michael C. Addison of Addison Law Office, P.A., Tampa, for Appellee Kevin Paul O'Connor.

No appearance, for remaining Appellee.

PER CURIAM.

In the order on appeal, the trial court awarded Kevin and Fran O'Connor attorney's fees and costs pursuant to an offer of judgment made under section 768.79, Florida Statutes (2013). We affirm the award of attorney's fees without comment. We reverse the costs award in two respects. First, as the O'Connors correctly concede, the trial court made a mistake by awarding costs for expert witness fees absent testimony concerning the reasonableness and necessity of the fee-which it was required to take upon Mr. Wedmore's timely objection. *See* *Field Club, Inc. v. Alario*, 180 So.3d 1138, 1141 (Fla. 2d DCA 2015). Second, the order incorrectly assessed costs for medical record copies at a rate in excess of the reasonable rate set by Florida Administrative Code Rule 64B8-10.003(2). We remand with instructions for the trial court to (1) as the O'Connors suggest, deduct the expert witness fees from the award of costs, *see* *Alario*, 180 So.3d at 1142, and (2) determine a reasonable amount of costs for copies of medical records and include only those reasonable costs in the cost award, *see* *Rodriguez v. Campbell*, 720 So.2d 266, 268 (Fla. 4th DCA 1998).

Affirmed in part, reversed in part, and remanded with instructions.

LaROSE, C.J., and SILBERMAN and SALARIO, JJ., Concur.
**Exhibit 32.1****Certification of CEO and CFO Pursuant to****18 U.S.C. Section 1350,****as Adopted Pursuant to****Section 906 of the Sarbanes-Oxley Act of 2002**     In connection with the Annual Report onForm 10-K ofoptionsXpress Holdings, Inc. (the “Company”) for theyear ended December 31, 2005 as filed with the Securitiesand Exchange Commission on the date hereof (the“Report”), David S. Kalt, as Chief Executive Officerof the Company, and David A. Fisher, as Chief Financial Officerof the Company, each hereby certifies, pursuant to18 U.S.C. § 1350, as adopted pursuant to§ 906 of the Sarbanes-Oxley Act of 2002, that, to thebest of his knowledge:          (1) The Report fully complies with the requirements of    Section 13(a) or 15(d) of the Securities Exchange Act of    1934; and           (2) The information contained in the Report fairly    presents, in all material respects, the financial condition and    results of operations of the Company.     /s/ DAVID S. KALT       Name: David S. Kalt     Title: Chief Executive OfficerDate: March 29, 2006     /s/ DAVID A. FISHER       Name: David A. Fisher     Title: Chief Financial OfficerDate: March 29, 2006     This certification accompanies the Report pursuant to§ 906 of the Sarbanes-Oxley Act of 2002 and shall not,except to the extent required by the Sarbanes-Oxley Act of 2002,be deemed filed by the Company for purposes of §18 of theSecurities Exchange Act of 1934, as amended.     A signed original of this written statement required by§ 906 of the Sarbanes-Oxley Act of 2002 has beenprovided to the Company and will be retained by the Company andfurnished to the Securities and Exchange Commission or its staffupon request.
Johnny BRADY, Appellant, v. The STATE of Florida, Appellee.

No. 3D17-2194

District Court of Appeal of Florida, Third District.

Opinion filed October 25, 2017

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
```

[Federal Register Volume 74, Number 64 (Monday, April 6, 2009)]
[Notices]
[Page 15500]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-7709]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Complementary & Alternative Medicine; Notice 
of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Complementary and 
Alternative Medicine Special Emphasis Panel Clinical Sciences.
    Date: June 22-23, 2009.
    Time: 8 a.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military 
Road, NW., Washington, DC 20015.
    Contact Person: Laurie Friedman Donze, PhD, Scientific Review 
Officer, Office of Scientific Review, National Center for 
Complementary, and Alternative Medicine, NIH, 6707 Democracy Blvd., 
Suite 401, Bethesda, MD 20892, 301-402-1030, [email protected].

    Dated: March 31, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
 [FR Doc. E9-7709 Filed 4-3-09; 8:45 am]
BILLING CODE 4140-01-P
```
[Federal Register Volume 83, Number 12 (Thursday, January 18, 2018)]
[Notices]
[Page 2617]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-00757]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[S-185-2017]


Approval of Subzone Status; Orgill, Inc., Tifton, Georgia

    On November 22, 2017, the Executive Secretary of the Foreign-Trade 
Zones (FTZ) Board docketed an application submitted by the Brunswick 
and Glenn County Development Authority, grantee of FTZ 144, requesting 
subzone status subject to the existing activation limit of FTZ 144, on 
behalf of Orgill, Inc., in Tifton, Georgia.
    The application was processed in accordance with the FTZ Act and 
Regulations, including notice in the Federal Register inviting public 
comment (82 FR 56211, November 28, 2017). The FTZ staff examiner 
reviewed the application and determined that it meets the criteria for 
approval. Pursuant to the authority delegated to the FTZ Board 
Executive Secretary (15 CFR Sec. 400.36(f)), the application to 
establish Subzone 144C was approved on January 11, 2018, subject to the 
FTZ Act and the Board's regulations, including Section 400.13, and 
further subject to FTZ 144's 2,000-acre activation limit.

    Dated: January 11, 2018.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. 2018-00757 Filed 1-17-18; 8:45 am]
 BILLING CODE 3510-DS-P
Exhibit 32.2
**SECTION 906 CERTIFICATION**
     In connection with the quarterly report of Landmark Land Company, Inc.(the “Company”) on Form 10-QSB for the fiscal quarter ended March 31, 2004 asfiled with the Securities and Exchange Commission on the date hereof (the“Report”), I, Joe V. Olree, Vice President and Chief Financial Officer of theCompany, certify to my knowledge, pursuant to 18 U.S.C. Section 1350, asadopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:
1. The Report fully complies with the requirements of Section 13(a) or 15(d)of the Securities Exchange Act of 1934; and 2. The information contained in the Report fairly presents, in all materialrespects, the financial condition and result of operations of the Company.   May 10, 2004 /s/ JOE V. OLREE   Joe V. OlreeVice President and Chief Financial OfficerLandmark Land Company, Inc.